Paeds Cases · infectious-diseases
Urinary tract infection and pyelonephritis: Case
Clinical case of a febrile young infant with vomiting and irritability found to have Escherichia coli pyelonephritis, covering urine sampling before antibiotics, urinalysis and culture interpretation, empiric therapy and the oral versus intravenous decision, and selective follow-up imaging.
On this page & tools
Target exams
This six-week-old infant presents with fever, vomiting, and reduced feeding, which together with a positive urine sample make pyelonephritis the working diagnosis. Infants under three months are the highest-risk group for UTI complications, with a non-negligible risk of bacteraemia and immature immune responses, so this child needs a lower threshold for investigation and parenteral therapy than an older infant. [1]
Clinical findings
The key findings are the young age, the fever with non-specific features rather than localising urinary symptoms, and the positive urine. In an infant this young, dysuria and flank pain cannot be reported, so fever, irritability, poor feeding, and vomiting are the presenting picture. The suprapubic aspirate growing Escherichia coli with both leucocyte esterase and nitrites positive confirms true infection rather than contamination, because a suprapubic specimen is the gold standard for sterility and any growth of a single uropathogen is significant. [1]
Because he is under one month beyond the neonatal period and febrile, the standard of care includes a full sepsis evaluation with blood cultures and consideration of cerebrospinal fluid analysis, and parenteral antibiotics rather than oral therapy. A raised creatinine or hypertension would mandate urgent ultrasound to exclude obstruction, and a palpable bladder or abdominal mass would raise concern for posterior urethral valves in a boy. [1]
Management
The empiric regimen for a febrile infant this young is intravenous ceftriaxone 50 mg per kilogram daily, because oral therapy is not appropriate under one to two months and the risk of bacteraemia and rapid deterioration is higher. The culture and sensitivities will later guide any narrowing of therapy, but the first dose must be given as soon as the cultures are sampled and must not wait for the full workup. [2]
Once he is afebrile for 24 to 48 hours, tolerating feeds, and improving, switch to an oral agent guided by sensitivities to complete a 7 to 10 day course for pyelonephritis. Review at 48 hours is essential: persistent fever or a failure to improve prompts reassessment for resistant organism, obstruction, or complication and urgent imaging. [2]
Complications and follow-up
The defining long-term complication is renal scarring, which affects roughly 10 to 15 per cent of children after a first febrile UTI and is highest in the youngest infants. Because he is six weeks old, his scarring risk is among the highest, so a DMSA scan performed four to six months after the infection is warranted to detect any permanent scar, alongside a renal ultrasound during the acute illness to exclude structural abnormality given his young age. [3]
Any confirmed scarring mandates lifelong annual blood pressure measurement and renal function surveillance, because hypertension and chronic kidney disease may emerge years later. Counsel the family about the prognosis honestly, provide a written safety-net for fever, poor feeding, or reduced urine output, and arrange a clear plan for review and imaging, because the consequences of a missed complication in this age group are severe. [3]
References
- [1]Roberts KB Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics, 2011.PMID 21873693
- [2]Hoberman A Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics, 1999.PMID 10390264
- [3]Shaikh N Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr, 2014.PMID 25089634